Dianthus Therapeutics Inc. Completes Phase 2 Trial Enrollment

Dianthus Therapeutics, Inc., a biotechnology company based in New York, United States, has announced the successful completion of enrollment for its Phase 2 MaGic trial of DNTH103, targeting Generalized Myasthenia Gravis. The company is now awaiting the top-line results, which are expected to be released in September.

Company Overview

Dianthus Therapeutics operates within the health care sector, focusing on the development of novel long-acting monoclonal antibody therapies aimed at treating severe autoimmune diseases. The company serves patients in the United States and is listed on the Nasdaq stock exchange. For more information, interested parties can visit the company’s official website at www.dianthustx.com .

Financial Snapshot

As of the last trading day on May 8, 2025, Dianthus Therapeutics’ stock price was $19.95 USD. Over the past year, the stock has experienced significant fluctuations, with a 52-week high of $32.27 USD on November 7, 2024, and a 52-week low of $13.365 USD on April 8, 2025. The company’s market capitalization stands at approximately $697.13 million USD.

The company’s financial metrics indicate a challenging valuation landscape, with a price-to-earnings ratio of -8.38 and a price-to-book ratio of 1.92. These figures reflect the company’s current financial performance and market perception.

Looking Ahead

The completion of the Phase 2 trial enrollment marks a significant milestone for Dianthus Therapeutics as it continues to advance its pipeline of therapies. The upcoming top-line results from the MaGic trial are highly anticipated by investors and stakeholders, as they will provide critical insights into the efficacy and safety of DNTH103 in treating Generalized Myasthenia Gravis.

For further updates and detailed information, stakeholders are encouraged to follow the company’s announcements and visit their official website.